Regeneron Pharmaceuticals' Change in Cash rose 495.10% to $497.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.3 million, marking a year-over-year increase of 437.80%. This contributed to the annual value of -$248.8 million for FY2024, which is 34.80% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Change in Cash stood at $497.5 million for Q3 2025, which was up 146.18% from -$1.1 billion recorded in Q2 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Change in Cash peaked at $1.4 billion during Q3 2021, and registered a low of -$2.0 billion during Q2 2023.
For the 3-year period, Regeneron Pharmaceuticals' Change in Cash averaged around -$55.1 million, with its median value being $210.5 million (2023).
Per our database at Business Quant, Regeneron Pharmaceuticals' Change in Cash tumbled by 4,106.28% in 2023 and then skyrocketed by 571.88% in 2025.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Change in Cash stood at -$546.8 million in 2021, then rose by 29.52% to -$385.4 million in 2022, then spiked by 249.87% to $577.6 million in 2023, then dropped by 17.38% to $477.2 million in 2024, then skyrocketed by 495.10% to $497.5 million in 2025.
Its last three reported values are $497.5 million in Q3 2025, -$1.1 billion for Q2 2025, and $604.0 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value